New Stock News | Jinfang Pharmaceuticals once again submits application to Hong Kong Stock Exchange, focusing on the fields of oncology, autoimmunity, and inflammatory diseases.

According to the disclosure by the Hong Kong Stock Exchange on January 10th, Jinfa Pharmaceutical Technology (Shanghai) Co., Ltd. (referred to as Jinfa Medicine) has submitted its listing application to the main board of the Hong Kong Stock Exchange, with CITIC SEC as its exclusive sponsor. The company previously submitted the application to the Hong Kong Stock Exchange on December 27, 2024. The prospectus shows that Jinfa Medicine was established in 2017 and is a biopharmaceutical company in the marketization stage, focusing on innovative and effective treatment solutions in the areas of oncology, autologous immunity, and inflammatory diseases. As of December 21, 2024, Jinfa Medicine has established a continuously updated product pipeline, including eight candidate drugs, with five of them in the clinical development stage. The company has two core products - GFH925 and GFH312. GFH925 (fulzerasib, trade name Daburte) is an innovative drug independently discovered by the company, which has been commercially approved in China for the treatment of advanced non-small cell lung cancer (NSCLC). It is the first in China and the third globally approved selective Kirsten rat sarcoma (KRAS) G12C inhibitor. GFH312 is a high-efficiency small molecule inhibitor developed by the company, which can selectively inhibit the kinase activity of receptor-interacting serine/threonine-protein kinase 1 (RIPK1). The company has obtained FDA approval for an IND to conduct a Phase II clinical trial in the United States, to evaluate the safety and efficacy of GFH312 in patients with peripheral arterial disease (PAD) accompanied by intermittent claudication (IC). In addition to the company's core products, Jinfa Medicine is also building a comprehensive and differentiated RAS product matrix, including GFH375, an orally bioavailable KRAS G12D small molecule inhibitor. In addition to the innovative RAS matrix, Jinfa Medicine is also committed to enriching its product pipeline with combinations such as GFS202A, a dual-specific antibody developed by the company targeting GDF15 and IL-6. The diversified product pipeline is a natural output of Jinfa Medicine's validated comprehensive research and development platform, which covers target discovery, molecule discovery and evaluation, translational science, global clinical development, and is complemented by the company's expertise in key chemistry, manufacturing, and controls (CMC) aspects such as formulation research and quality analysis. Financially, in the year 2022 and 2023, Jinfa Medicine's revenue was approximately 105 million and 73.734 million RMB respectively. In the year 2022, 2023, and the six months ending on June 30, 2023 and 2024, the company incurred losses of approximately 275 million, 508 million, 214 million, and 449 million RMB respectively.